Researchers from the EUbOPEN consortium used a high-quality chemical probe - a targeted NUDT5 degrader (PROTAC) - to uncover a previously unknown “handbrake” mechanism controlling purine biosynthesis, helping to explain why some cancers are resistant to nucleoside-based therapies, as reported in Science.
